These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model. Bellmann L; Cappellano G; Schachtl-Riess JF; Prokopi A; Seretis A; Ortner D; Tripp CH; Brinckerhoff CE; Mullins DW; Stoitzner P Int J Cancer; 2020 Mar; 146(5):1409-1420. PubMed ID: 31702822 [TBL] [Abstract][Full Text] [Related]
6. HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. Gallagher SJ; Gunatilake D; Beaumont KA; Sharp DM; Tiffen JC; Heinemann A; Weninger W; Haass NK; Wilmott JS; Madore J; Ferguson PM; Rizos H; Hersey P Int J Cancer; 2018 May; 142(9):1926-1937. PubMed ID: 29210065 [TBL] [Abstract][Full Text] [Related]
7. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955 [TBL] [Abstract][Full Text] [Related]
8. BRAF Inhibitor Resistance Confers Increased Sensitivity to Mitotic Inhibitors. Misek SA; Foda BM; Dexheimer TS; Akram M; Conrad SE; Schmidt JC; Neubig RR; Gallo KA Front Oncol; 2022; 12():766794. PubMed ID: 35444937 [TBL] [Abstract][Full Text] [Related]
9. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. Chan MM; Haydu LE; Menzies AM; Azer MW; Klein O; Lyle M; Clements A; Guminski A; Kefford RF; Long GV Cancer; 2014 Oct; 120(20):3142-53. PubMed ID: 24985732 [TBL] [Abstract][Full Text] [Related]
10. Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Zhang C; Wang Y; Zhou Z; Zhang J; Tian Z Cancer Immunol Immunother; 2009 Aug; 58(8):1275-85. PubMed ID: 19139882 [TBL] [Abstract][Full Text] [Related]
11. Radiosensitization effect by HDAC inhibition improves NKG2D-dependent natural killer cytotoxicity in hepatocellular carcinoma. Liu YF; Chiang Y; Hsu FM; Tsai CL; Cheng JC Front Oncol; 2022; 12():1009089. PubMed ID: 36185276 [TBL] [Abstract][Full Text] [Related]
12. BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells. Atay C; Kwak T; Lavilla-Alonso S; Donthireddy L; Richards A; Moberg V; Pilon-Thomas S; Schell M; Messina JL; Rebecca VW; Xiao M; Tan J; Zhang G; Weber JS; Herlyn M; Sarnaik AA; Gabrilovich DI Clin Cancer Res; 2019 May; 25(9):2783-2794. PubMed ID: 30765391 [TBL] [Abstract][Full Text] [Related]
13. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
14. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634 [TBL] [Abstract][Full Text] [Related]
15. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma. Duggan MC; Stiff AR; Bainazar M; Regan K; Olaverria Salavaggione GN; Maharry S; Blachly JS; Krischak M; Walker CJ; Latchana N; Tridandapani S; de la Chapelle A; Eisfeld AK; Carson WE Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9629-9634. PubMed ID: 28827320 [TBL] [Abstract][Full Text] [Related]
16. Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463 [No Abstract] [Full Text] [Related]
17. Combination Treatment with the BRAF Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573 [TBL] [Abstract][Full Text] [Related]